{"transactions":[{"id":2273205,"issuer":{"id":6284,"kind":"organization","name":"PRECISION BIOSCIENCES INC","symbol":"DTIL"},"owners":[{"id":127367,"kind":"person","name":"Schinazi Raymond F","position":1,"cik":"0001397607","reported_name":"Schinazi Raymond F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-12T11:13:52.000Z","date":"2022-05-10","kind":"grant","acquired":true,"shares":156951,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests on the earlier to occur of (i) May 10, 2023 and (ii) the day immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in either case, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date."}],"balance_after":156951,"derivative":{"exercise_price":1.86,"expiration_date":"2032-05-09","underlying":"Common Stock","underlying_shares":156951},"source":{"system":"sec-edgar","filing":"0001209191-22-028445","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1357874/000120919122028445/doc4.xml","form_type":"4"}},{"id":2715978,"issuer":{"id":6284,"kind":"organization","name":"PRECISION BIOSCIENCES INC","symbol":"DTIL"},"owners":[{"id":127367,"kind":"person","name":"Schinazi Raymond F","position":1,"cik":"0001397607","reported_name":"Schinazi Raymond F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-12T20:07:09.000Z","date":"2021-05-10","kind":"grant","acquired":true,"shares":32800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests on the earlier of May 10, 2022 or the day immediately prior to the date of the next annual meeting of the Company's stockholders occurring after May 10, 2021, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date."}],"balance_after":32800,"derivative":{"exercise_price":8.07,"expiration_date":"2031-05-09","underlying":"Common Stock","underlying_shares":32800},"source":{"system":"sec-edgar","filing":"0001209191-21-032018","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1357874/000120919121032018/doc4.xml","form_type":"4"}},{"id":2725009,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":127367,"kind":"person","name":"Schinazi Raymond F","position":1,"cik":"0001397607","reported_name":"Schinazi Raymond F","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-05-06T22:00:16.000Z","date":"2021-05-04","kind":"sale","acquired":false,"shares":575000,"price":2.95,"value":1696250.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $2.60 to $3.25, inclusive. The Reporting Person undertakes to provide to Cocrystal Pharma, Inc., any security holder of Cocrystal Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the ranges set forth in footnote (1) to this Form 4."}],"balance_after":7674960,"source":{"system":"sec-edgar","filing":"0001493152-21-010669","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315221010669/ownership.xml","form_type":"4"}},{"id":3146891,"issuer":{"id":6284,"kind":"organization","name":"PRECISION BIOSCIENCES INC","symbol":"DTIL"},"owners":[{"id":127367,"kind":"person","name":"Schinazi Raymond F","position":1,"cik":"0001397607","reported_name":"Schinazi Raymond F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-05-15T20:00:12.000Z","date":"2020-05-13","kind":"grant","acquired":true,"shares":41038,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests on the earlier of May 13, 2021 or the day immediately prior to the date of the next annual meeting of the Company's stockholders occurring after May 13, 2020."}],"balance_after":41038,"derivative":{"exercise_price":6.62,"expiration_date":"2030-05-12","underlying":"Common Stock","underlying_shares":41038},"source":{"system":"sec-edgar","filing":"0001209191-20-029688","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1357874/000120919120029688/doc4.xml","form_type":"4"}},{"id":3386213,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":127367,"kind":"person","name":"Schinazi Raymond F","position":1,"cik":"0001397607","reported_name":"Schinazi Raymond F","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-10-29T21:03:31.000Z","date":"2019-10-25","kind":"purchase","acquired":true,"shares":7906,"price":1.15,"value":9091.9,"ownership":{"direct":true},"balance_after":9257863,"source":{"system":"sec-edgar","filing":"0001493152-19-016105","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315219016105/ownership.xml","form_type":"4"}},{"id":3386212,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":127367,"kind":"person","name":"Schinazi Raymond F","position":1,"cik":"0001397607","reported_name":"Schinazi Raymond F","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-10-29T21:03:31.000Z","date":"2019-10-24","kind":"purchase","acquired":true,"shares":5094,"price":1.15,"value":5858.1,"ownership":{"direct":true},"balance_after":9249957,"source":{"system":"sec-edgar","filing":"0001493152-19-016105","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315219016105/ownership.xml","form_type":"4"}},{"id":3386211,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":127367,"kind":"person","name":"Schinazi Raymond F","position":1,"cik":"0001397607","reported_name":"Schinazi Raymond F","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2019-10-29T21:03:31.000Z","date":"2019-10-23","kind":"purchase","acquired":true,"shares":3935,"price":1.0386,"value":4086.891,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions at prices ranging from $0.965 to $1.08, inclusive. The reporting person undertakes to provide to Cocrystal Pharma, Inc., any security holder of Cocrystal Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in the footnote of this Form 4."}],"balance_after":9244863,"source":{"system":"sec-edgar","filing":"0001493152-19-016105","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315219016105/ownership.xml","form_type":"4"}},{"id":3567820,"issuer":{"id":6284,"kind":"organization","name":"PRECISION BIOSCIENCES INC","symbol":"DTIL"},"owners":[{"id":127367,"kind":"person","name":"Schinazi Raymond F","position":1,"cik":"0001397607","reported_name":"Schinazi Raymond F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2019-04-02T21:19:17.000Z","date":"2019-04-01","kind":"exercise","acquired":false,"shares":119761,"ownership":{"direct":false,"nature":"By RFS Partners, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series B Preferred Stock automatically converted into the common stock of Precision BioSciences, Inc. (the \"Issuer\") on a 2.134686-to-1 basis (after giving effect to the Issuer's previously completed reverse stock split) upon the closing of the Issuer's initial public offering (the \"IPO\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Series B Preferred Stock automatically converted into the common stock of Precision BioSciences, Inc. (the \"Issuer\") on a 2.134686-to-1 basis (after giving effect to the Issuer's previously completed reverse stock split) upon the closing of the Issuer's initial public offering (the \"IPO\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Series B Preferred Stock automatically converted into the common stock of Precision BioSciences, Inc. (the \"Issuer\") on a 2.134686-to-1 basis (after giving effect to the Issuer's previously completed reverse stock split) upon the closing of the Issuer's initial public offering (the \"IPO\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series B Preferred Stock automatically converted into the common stock of Precision BioSciences, Inc. (the \"Issuer\") on a 2.134686-to-1 basis (after giving effect to the Issuer's previously completed reverse stock split) upon the closing of the Issuer's initial public offering (the \"IPO\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities reported herein are held of record by RFS Partners LP (\"RFS\"). RFS & Associates, LLC (\"RFS & Associates\") is the general partner of RFS, and the reporting person is a limited partner of RFS as well as the manager of RFS & Associates. The reporting person disclaims beneficial ownership of the securities held by RFS, except to the extent of any pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":56102},"source":{"system":"sec-edgar","filing":"0001209191-19-022658","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1357874/000120919119022658/doc4.xml","form_type":"4"}},{"id":3567819,"issuer":{"id":6284,"kind":"organization","name":"PRECISION BIOSCIENCES INC","symbol":"DTIL"},"owners":[{"id":127367,"kind":"person","name":"Schinazi Raymond F","position":1,"cik":"0001397607","reported_name":"Schinazi Raymond F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Convertible Promissory Note","published_at":"2019-04-02T21:19:17.000Z","date":"2019-04-01","kind":"exercise","acquired":false,"reported_value":502466,"ownership":{"direct":false,"nature":"By RFS Partners, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 1, 2019, RFS acquired a convertible promissory note in the principal amount of $500,000 (the \"2019 Note\") from the Issuer.  Effective upon the closing of the IPO on April 1, 2019, the 2019 Note, including accrued interest, converted into 36,946 shares of the Issuer's common stock at a price per share equal to $13.60, which represented 85% of the price per share in the IPO."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On March 1, 2019, RFS acquired a convertible promissory note in the principal amount of $500,000 (the \"2019 Note\") from the Issuer.  Effective upon the closing of the IPO on April 1, 2019, the 2019 Note, including accrued interest, converted into 36,946 shares of the Issuer's common stock at a price per share equal to $13.60, which represented 85% of the price per share in the IPO."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On March 1, 2019, RFS acquired a convertible promissory note in the principal amount of $500,000 (the \"2019 Note\") from the Issuer.  Effective upon the closing of the IPO on April 1, 2019, the 2019 Note, including accrued interest, converted into 36,946 shares of the Issuer's common stock at a price per share equal to $13.60, which represented 85% of the price per share in the IPO."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities reported herein are held of record by RFS Partners LP (\"RFS\"). RFS & Associates, LLC (\"RFS & Associates\") is the general partner of RFS, and the reporting person is a limited partner of RFS as well as the manager of RFS & Associates. The reporting person disclaims beneficial ownership of the securities held by RFS, except to the extent of any pecuniary interest therein."}],"balance_after":0,"derivative":{"exercise_price":13.6,"underlying":"Common Stock","underlying_shares":36946},"source":{"system":"sec-edgar","filing":"0001209191-19-022658","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1357874/000120919119022658/doc4.xml","form_type":"4"}},{"id":3567818,"issuer":{"id":6284,"kind":"organization","name":"PRECISION BIOSCIENCES INC","symbol":"DTIL"},"owners":[{"id":127367,"kind":"person","name":"Schinazi Raymond F","position":1,"cik":"0001397607","reported_name":"Schinazi Raymond F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-04-02T21:19:17.000Z","date":"2019-04-01","kind":"exercise","acquired":true,"shares":56102,"ownership":{"direct":false,"nature":"By RFS Partners, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Series B Preferred Stock automatically converted into the common stock of Precision BioSciences, Inc. (the \"Issuer\") on a 2.134686-to-1 basis (after giving effect to the Issuer's previously completed reverse stock split) upon the closing of the Issuer's initial public offering (the \"IPO\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities reported herein are held of record by RFS Partners LP (\"RFS\"). RFS & Associates, LLC (\"RFS & Associates\") is the general partner of RFS, and the reporting person is a limited partner of RFS as well as the manager of RFS & Associates. The reporting person disclaims beneficial ownership of the securities held by RFS, except to the extent of any pecuniary interest therein."}],"balance_after":93048,"source":{"system":"sec-edgar","filing":"0001209191-19-022658","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1357874/000120919119022658/doc4.xml","form_type":"4"}},{"id":3567817,"issuer":{"id":6284,"kind":"organization","name":"PRECISION BIOSCIENCES INC","symbol":"DTIL"},"owners":[{"id":127367,"kind":"person","name":"Schinazi Raymond F","position":1,"cik":"0001397607","reported_name":"Schinazi Raymond F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-04-02T21:19:17.000Z","date":"2019-04-01","kind":"exercise","acquired":true,"shares":36946,"price":13.6,"value":502465.6,"ownership":{"direct":false,"nature":"By RFS Partners, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities reported herein are held of record by RFS Partners LP (\"RFS\"). RFS & Associates, LLC (\"RFS & Associates\") is the general partner of RFS, and the reporting person is a limited partner of RFS as well as the manager of RFS & Associates. The reporting person disclaims beneficial ownership of the securities held by RFS, except to the extent of any pecuniary interest therein."}],"balance_after":36946,"source":{"system":"sec-edgar","filing":"0001209191-19-022658","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1357874/000120919119022658/doc4.xml","form_type":"4"}},{"id":3573873,"issuer":{"id":6284,"kind":"organization","name":"PRECISION BIOSCIENCES INC","symbol":"DTIL"},"owners":[{"id":127367,"kind":"person","name":"Schinazi Raymond F","position":1,"cik":"0001397607","reported_name":"Schinazi Raymond F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Convertible Promissory Note","published_at":"2019-03-29T22:36:46.000Z","date":"2019-03-27","kind":"other","acquired":true,"price":500000,"reported_value":502466,"ownership":{"direct":false,"nature":"By RFS Partners, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On March 1, 2019, RFS Partners LP (\"RFS\") acquired a convertible promissory note in the principal amount of $500,000 (the \"2019 Note\") from Precision BioSciences, Inc. (the \"Issuer\").  In connection with the pricing of the Issuer's initial public offering on March 27, 2019 (the \"IPO\"), the conversion price of the 2019 Note became fixed at 85% of the price per share in the IPO, and the 2019 Note became automatically convertible into shares of the Issuer's common stock at the closing of the IPO."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On March 1, 2019, RFS Partners LP (\"RFS\") acquired a convertible promissory note in the principal amount of $500,000 (the \"2019 Note\") from Precision BioSciences, Inc. (the \"Issuer\").  In connection with the pricing of the Issuer's initial public offering on March 27, 2019 (the \"IPO\"), the conversion price of the 2019 Note became fixed at 85% of the price per share in the IPO, and the 2019 Note became automatically convertible into shares of the Issuer's common stock at the closing of the IPO."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On March 1, 2019, RFS Partners LP (\"RFS\") acquired a convertible promissory note in the principal amount of $500,000 (the \"2019 Note\") from Precision BioSciences, Inc. (the \"Issuer\").  In connection with the pricing of the Issuer's initial public offering on March 27, 2019 (the \"IPO\"), the conversion price of the 2019 Note became fixed at 85% of the price per share in the IPO, and the 2019 Note became automatically convertible into shares of the Issuer's common stock at the closing of the IPO."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The 2019 Note is held of record by RFS. RFS & Associates, LLC (\"RFS & Associates\") is the general partner of RFS, and the reporting person is a limited partner of RFS as well as the manager of RFS & Associates. The reporting person disclaims beneficial ownership of the 2019 Note, except to the extent of any pecuniary interest therein."}],"derivative":{"exercise_price":13.6,"underlying":"Common Stock","underlying_shares":36946},"source":{"system":"sec-edgar","filing":"0001209191-19-021848","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1357874/000120919119021848/doc4.xml","form_type":"4"}},{"id":3573872,"issuer":{"id":6284,"kind":"organization","name":"PRECISION BIOSCIENCES INC","symbol":"DTIL"},"owners":[{"id":127367,"kind":"person","name":"Schinazi Raymond F","position":1,"cik":"0001397607","reported_name":"Schinazi Raymond F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-03-29T22:36:46.000Z","date":"2019-03-27","kind":"grant","acquired":true,"shares":34544,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 34% of the underlying shares on March 27, 2020 and vests in equal installments at the end of each successive three-month period over the following 24 months."}],"balance_after":34544,"derivative":{"exercise_price":16,"expiration_date":"2029-03-26","underlying":"Common Stock","underlying_shares":34544},"source":{"system":"sec-edgar","filing":"0001209191-19-021848","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1357874/000120919119021848/doc4.xml","form_type":"4"}},{"id":3809001,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":127367,"kind":"person","name":"Schinazi Raymond F","position":1,"cik":"0001397607","reported_name":"Schinazi Raymond F","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2018-09-24T20:43:43.000Z","date":"2018-09-21","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options vest as follows: 1/4 will vest on the one year anniversary of the grant date and the remaining 3/4 will vest in 12 equal quarterly increments."}],"balance_after":50000,"derivative":{"exercise_price":2.78,"expiration_date":"2028-09-20","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001493152-18-013665","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315218013665/ownership.xml","form_type":"4"}},{"id":3934621,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":127367,"kind":"person","name":"Schinazi Raymond F","position":1,"cik":"0001397607","reported_name":"Schinazi Raymond F","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"8% Convertible Note","published_at":"2018-05-14T20:01:12.000Z","date":"2018-05-10","kind":"exercise","acquired":false,"shares":263158,"price":500000,"value":131579000000.0,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The amount of securities beneficially owned and the conversion prices have been adjusted for the one-for-30 reverse stock split effective January 24, 2018."}],"balance_after":263158,"derivative":{"exercise_price":1.9,"exercise_date":"2018-05-10","expiration_date":"2019-11-24","underlying":"Common Stock","underlying_shares":263158},"source":{"system":"sec-edgar","filing":"0001493152-18-006784","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315218006784/form4.xml","form_type":"4"}},{"id":3934620,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":127367,"kind":"person","name":"Schinazi Raymond F","position":1,"cik":"0001397607","reported_name":"Schinazi Raymond F","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"8% Convertible Note","published_at":"2018-05-14T20:01:12.000Z","date":"2018-05-10","kind":"grant","acquired":true,"shares":263158,"price":500000,"value":131579000000.0,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The amount of securities beneficially owned and the conversion prices have been adjusted for the one-for-30 reverse stock split effective January 24, 2018."},{"field":"security","element":"securityTitle","label":"F4","text":"In accordance with Rule 16b-3, in advance of the effectuation of the transactions reported, the issuer's board of directors approved an amendment to the convertible note held by the reporting person who is a director and 10% beneficial owner of the issuer. The amendment of the outstanding convertible note is reported as a cancellation of the \"old\" note and the grant of a replacement note."}],"balance_after":263158,"derivative":{"exercise_price":1.9,"exercise_date":"2018-05-10","expiration_date":"2019-11-24","underlying":"Common Stock","underlying_shares":263158},"source":{"system":"sec-edgar","filing":"0001493152-18-006784","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315218006784/form4.xml","form_type":"4"}},{"id":3934619,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":127367,"kind":"person","name":"Schinazi Raymond F","position":1,"cik":"0001397607","reported_name":"Schinazi Raymond F","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"8% Convertible Note","published_at":"2018-05-14T20:01:12.000Z","date":"2018-05-10","kind":"disposition_to_issuer","acquired":false,"shares":61728,"price":500000,"value":30864000000.0,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The amount of securities beneficially owned and the conversion prices have been adjusted for the one-for-30 reverse stock split effective January 24, 2018."},{"field":"security","element":"securityTitle","label":"F4","text":"In accordance with Rule 16b-3, in advance of the effectuation of the transactions reported, the issuer's board of directors approved an amendment to the convertible note held by the reporting person who is a director and 10% beneficial owner of the issuer. The amendment of the outstanding convertible note is reported as a cancellation of the \"old\" note and the grant of a replacement note."}],"balance_after":61728,"derivative":{"exercise_price":8.1,"exercise_date":"2017-11-24","expiration_date":"2019-11-24","underlying":"Common Stock","underlying_shares":61728},"source":{"system":"sec-edgar","filing":"0001493152-18-006784","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315218006784/form4.xml","form_type":"4"}},{"id":3934618,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":127367,"kind":"person","name":"Schinazi Raymond F","position":1,"cik":"0001397607","reported_name":"Schinazi Raymond F","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-05-14T20:01:12.000Z","date":"2018-05-10","kind":"grant","acquired":true,"shares":10209,"price":1.9,"value":19397.1,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The amount of securities beneficially owned and the conversion prices have been adjusted for the one-for-30 reverse stock split effective January 24, 2018."},{"field":"kind","element":"transactionCoding","label":"F3","text":"The reporting person was issued common stock in lieu of accrued interest owed in connection with the convertible note described in Table II."}],"balance_after":995593,"source":{"system":"sec-edgar","filing":"0001493152-18-006784","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315218006784/form4.xml","form_type":"4"}},{"id":3934617,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":127367,"kind":"person","name":"Schinazi Raymond F","position":1,"cik":"0001397607","reported_name":"Schinazi Raymond F","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-05-14T20:01:12.000Z","date":"2018-05-10","kind":"exercise","acquired":true,"shares":263158,"price":1.9,"value":500000.2,"ownership":{"direct":false,"nature":"By LP"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The amount of securities beneficially owned and the conversion prices have been adjusted for the one-for-30 reverse stock split effective January 24, 2018."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The reporting person was issued common stock in connection with the conversion of a convertible note, as amended, at $1.90 per share. See Table II for a description of the convertible note."}],"balance_after":985384,"source":{"system":"sec-edgar","filing":"0001493152-18-006784","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315218006784/form4.xml","form_type":"4"}},{"id":3944181,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":127367,"kind":"person","name":"Schinazi Raymond F","position":1,"cik":"0001397607","reported_name":"Schinazi Raymond F","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-05-07T22:21:41.000Z","date":"2018-05-03","kind":"grant","acquired":true,"shares":420737,"price":1.9,"value":799400.3,"ownership":{"direct":false,"nature":"By LP"},"balance_after":722226,"source":{"system":"sec-edgar","filing":"0001493152-18-006360","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315218006360/form4.xml","form_type":"4"}},{"id":4137828,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":127367,"kind":"person","name":"Schinazi Raymond F","position":1,"cik":"0001397607","reported_name":"Schinazi Raymond F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"8% Convertible Note","published_at":"2017-12-08T22:42:19.000Z","date":"2017-11-24","kind":"grant","acquired":true,"shares":1851851,"price":500000,"value":925925500000.0,"ownership":{"direct":false,"nature":"By LP"},"balance_after":1851851,"derivative":{"exercise_price":0.27,"exercise_date":"2017-11-24","expiration_date":"2019-11-24","underlying":"Common Stock","underlying_shares":1851851},"source":{"system":"sec-edgar","filing":"0001493152-17-014433","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315217014433/form4.xml","form_type":"4"}},{"id":4257693,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":127367,"kind":"person","name":"Schinazi Raymond F","position":1,"cik":"0001397607","reported_name":"Schinazi Raymond F","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2017-07-13T20:05:53.000Z","date":"2017-07-11","kind":"exercise","acquired":false,"shares":1706978,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":0.047,"exercise_date":"2014-11-25","expiration_date":"2018-01-02","underlying":"Common Stock","underlying_shares":1706978},"source":{"system":"sec-edgar","filing":"0001493152-17-007777","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315217007777/form4.xml","form_type":"4"}},{"id":4257692,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":127367,"kind":"person","name":"Schinazi Raymond F","position":1,"cik":"0001397607","reported_name":"Schinazi Raymond F","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-07-13T20:05:53.000Z","date":"2017-07-11","kind":"exercise","acquired":true,"shares":1706978,"price":0.047,"value":80227.966,"ownership":{"direct":true},"balance_after":277227831,"source":{"system":"sec-edgar","filing":"0001493152-17-007777","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315217007777/form4.xml","form_type":"4"}},{"id":4346600,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":127367,"kind":"person","name":"Schinazi Raymond F","position":1,"cik":"0001397607","reported_name":"Schinazi Raymond F","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-04-24T20:15:57.000Z","date":"2017-04-20","kind":"grant","acquired":true,"shares":4166667,"price":0.24,"value":1000000.08,"ownership":{"direct":false,"nature":"By LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a purchase meeting the requirements of Rule 16b-3."}],"balance_after":9044717,"source":{"system":"sec-edgar","filing":"0001493152-17-004329","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315217004329/form4.xml","form_type":"4"}},{"id":4610966,"issuer":{"id":7621,"kind":"organization","name":"Cocrystal Pharma, Inc."},"owners":[{"id":127367,"kind":"person","name":"Schinazi Raymond F","position":1,"cik":"0001397607","reported_name":"Schinazi Raymond F","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2016-09-06T20:15:15.000Z","date":"2016-09-01","kind":"purchase","acquired":true,"shares":4878050,"price":0.41,"value":2000000.5,"ownership":{"direct":false,"nature":"By LLC"},"balance_after":4878050,"source":{"system":"sec-edgar","filing":"0001415889-16-007051","document":"form4-09062016_040905.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1412486/000141588916007051/form4-09062016_040905.xml","form_type":"4"}}]}